Forteo medication side effects
August 17 2015
Forteo is a prescription medication approved for use in postmenopausal women with osteoporosis who are at high risk for having broken bones (fractures) due to osteoporosis. This medication is also approved for men with osteoporosis who are at high risk for having broken bones (fractures) due to osteoporosis.
Adverse reactions, side effects
J Bone Miner Metab. 2014 Feb 20. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. PTH (teriparatide) is used in the treatment of osteoporosis, and can sometimes cause transient hypercalcemia, but to date there have been no reports of persistent hypercalcemia and hypophosphatemia resulting from its use. We describe a case with marked hypophosphatemia and hypercalcemia associated with the use of teriparatide. The patient was a 49-year-old woman who was followed up for acute intermittent porphyria and glucocorticoid-induced osteoporosis (following administration of prednisolone at 22.5 mg/day), and presented with unexplained fracture of the left tibia, for which treatment with teriparatide at 20 μg/day was started. Two weeks after treatment with teriparatide, the patient developed hypophosphatemia, hypercalcemia, hyperalkaline phosphatasemia, low TmP/GFR, FEca, BAP, and urinary NT×, with low intact PTH. These changes were considered to be related to teriparatide. Cessation of teriparatide treatment resulted in normalization of all parameters at 10 weeks (serum P 3.6 mg/dl, corrected Ca 8.8 mg/dl, ALP 273 IU/l, intact PTH 63 pg/ml). The observed abnormalities were considered to be in part related to acute intermittent porphyria, which is known to delay hepatic teriparatide clearance, with subsequent delay of PTH action despite its intermittent use, resulting in hypercalcemia and hypophosphatemia.
Clin Cases Miner Bone Metab. 2013 Sep. Tensile type of stress fracture neck of femur: role of teriparatide in the process of healing in a high risk patient for impaired healing of fracture.Malhotra R, Meena S, Digge VK.Author informationAbstractNeck of femur stress fractures, whilst representing only around 8% of stress fractures is associated with a high morbidity. Radiographically, stress fractures of neck of femur are classified into compression and tensile type. Tensile type is notorious for displacement and hence prophylactic surgery is indicated, unlike stable compression fracture. Currently recombinant Parathyroid Hormone (PTH) is used in the treatment of osteoporosis. More recently, many animal studies suggest that the recombinant PTH is helpful to achieve fracture union in normal model and in impaired fracture healing model. We achieved union in a 62-year-old postmenopausal female with tensile type of fracture neck of femur, who had multiple comorbidities for impaired healing of fracture, without any surgical intervention using systemic recombinant PTH.
The major safety concern associated with the use of bisphosphonates is the development of femoral shaft stress fractures.
My doctor has prescribed Forteo, an injectible drug that is supposed to build back lost bone matter. I was wondering if you know of any independent research studies that test the safety of the drug. I realize it hasn't been out long but any information would help. I have mild to moderate osteoporosis but don't want to take Fosamex, Boniva and the like.